文献

J-GLOBAL ID：201702247607906145   整理番号：17A1099787

非ヒト霊長類におけるV3グリカン広範囲中和エピトープに対する高マンノース依存性中和抗体のワクチン誘導【Powered by NICT】

Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates

著者 (59件)： Saunders Kevin O. (Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA) ,  Saunders Kevin O. (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Nicely Nathan I. (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Nicely Nathan I. (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Wiehe Kevin (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Wiehe Kevin (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Bonsignori Mattia (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Bonsignori Mattia (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Meyerhoff R. Ryan (Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA) ,  Meyerhoff R. Ryan (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Parks Robert (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Parks Robert (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Walkowicz William E. (Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA) ,  Aussedat Baptiste (Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA) ,  Wu Nelson R. (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Wu Nelson R. (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Cai Fangping (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Cai Fangping (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Vohra Yusuf (Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA) ,  Park Peter K. (Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA) ,  Eaton Amanda (Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA) ,  Eaton Amanda (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Go Eden P. (University of Kansas, Lawrence, KS 66045, USA) ,  Sutherland Laura L. (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Sutherland Laura L. (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Scearce Richard M. (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Scearce Richard M. (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Barouch Dan H. (Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA) ,  Zhang Ruijun (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Zhang Ruijun (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Von Holle Tarra (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Von Holle Tarra (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Overman R. Glenn (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Overman R. Glenn (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Anasti Kara (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Anasti Kara (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Sanders Rogier W. (Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands) ,  Moody M. Anthony (Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA) ,  Moody M. Anthony (Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA) ,  Moody M. Anthony (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Kepler Thomas B. (Boston University, Boston, MA 02215, USA) ,  Korber Bette (LANL, Los Alamos, NM 87545, USA) ,  Desaire Heather (University of Kansas, Lawrence, KS 66045, USA) ,  Santra Sampa (Harvard Medical School, Boston, MA, 02215, USA) ,  Letvin Norman L. (Harvard Medical School, Boston, MA, 02215, USA) ,  Nabel Gary J. (Sanofi, Cambridge, MA 02139, USA) ,  Montefiori David C. (Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA) ,  Tomaras Georgia D. (Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA) ,  Tomaras Georgia D. (Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA) ,  Tomaras Georgia D. (Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA) ,  Tomaras Georgia D. (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Liao Hua-Xin (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Liao Hua-Xin (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Alam S. Munir (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Alam S. Munir (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA) ,  Danishefsky Samuel J. (Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA) ,  Haynes Barton F. (Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA) ,  Haynes Barton F. (Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA) ,  Haynes Barton F. (Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA)
資料名： Cell Reports  (Cell Reports)
巻： 18  号： 9  ページ： 2175-2188  発行年： 2017年 
JST資料番号： W3124A  ISSN： 2211-1247  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： HIV 1エンベロープ(Env)を標的とする広域中和抗体(bnAbs)の誘導はHIV-1ワクチン開発の目標である。bnAb標的はEnv第三可変ループ(V3)-グリカン部位である。免疫はV3グリカンbnAb結合部位に対する抗体を誘導できるかどうかを決定するために,V3高マンノースグリカンを発現するEnvと4年間にわたるザルを免疫した繰返した。Env免疫は中和HIV 1は初期bnAb B細胞系統メンバーにより共有されているだけ高マンノースグリカンa特性を発現している血漿抗体を誘発した。大まかに抗体を無力としてワクチン接種マカクからアカゲザル組換モノクローナル抗体は,同じアミノ酸でV3グリカン部位に結合した。グリカンに結合した抗体の構造は三可変重鎖相補性決定領域は,グリカンは挿入できる空洞を形成し,高マンノースグリカンを有する多数のHIV-1分離株を中和したことを明らかにした。このように,HIV-1Envワクチン接種はV3グリカンbnAb前駆体の特性を持つマンノース抗体を誘導した。Copyright 2017 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【Powered by NICT】

シソーラス用語： *エピトープ ,  *ヒト ,  *中和抗体 ,  HIV【ウイルス】 ,  アカゲザル ,  結合部位 ,  *ワクチン ,  前駆体 ,  モノクローナル抗体 ,  *抗体 ,  *中性化 ,  予防接種 ,  HIV1 ,  アミノ酸
準シソーラス用語： *グリカン , 【Automatic Indexing@JST】

著者キーワード (5件)： HIV ,  V3グリカン ,  予防接種 ,  グリカン ,  長期免疫

分類 (1件)： ウイルスの生化学  (EG04030F)

タイトルに関連する用語 (10件)： ヒト ,  霊長類 ,  グリカン ,  中和 ,  エピトープ ,  マンノース ,  依存性 ,  中和抗体 ,  ワクチン ,  誘導